Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are ... PR Newswire (press release) It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries' Treanda, Mundipharma's Ribomustin/Levact, Symbio Pharmaceuticals/Eisai's Treakisym) in combination with rituximab, ... |
